双相99mTc-MIBI SPECT/CT列线图鉴别非小细胞肺癌与良性肺部病变的前瞻性研究
前瞻性纳入103例患者共119个病灶(非小细胞肺癌92个、良性27个),行双相99mTc-MIBI SPECT/CT,按训练集83例、验证集36例建模。延迟相列线图AUC为0.893,优于临床模型(AUC 0.643,P=0.042),与影像组学模型(AUC 0.888)无显著差异(P=0.480);延迟相SPECT/CT影像组学AUC 0.768,显著高于单独CT的0.696和单独SPECT的0.768对比(P=0.042、P=0.038)。
要点
- 延迟相列线图AUC 0.893,优于临床模型AUC 0.643(P=0.042),与影像组学模型无显著差异。
- 延迟相SPECT/CT影像组学AUC 0.768,显著高于单独CT的0.696和单独SPECT的0.768(P=0.042、P=0.038)。
- 延迟相列线图与影像组学模型AUC高于早期相,但无统计学差异(P=0.831、P=0.568)。
核心结论
- 双相99mTc-MIBI SPECT/CT列线图及影像组学模型可有效预测非小细胞肺癌,延迟相SPECT/CT对诊断可能比早期相更具实用价值,但需在更大规模多中心队列中进一步验证。
研究设计与样本
- 前瞻性研究,纳入103例患者共119个病灶(非小细胞肺癌92个、良性肺部病变27个),平均年龄59.68±8.94岁,行双相99mTc-MIBI SPECT/CT,分为训练集83例和验证集36例。
诊断标准与关键数值
- 早期相临床模型AUC 0.571、影像组学模型AUC 0.830、列线图AUC 0.875。
- 延迟相临床模型AUC 0.643、影像组学模型AUC 0.888、列线图AUC 0.893。
- 早期相列线图优于临床模型(P=0.020)、与影像组学模型无显著差异(P=0.216),影像组学与临床模型无显著差异(P=0.103)。
- 延迟相列线图优于临床模型(P=0.042)、与影像组学模型无显著差异(P=0.480),影像组学优于临床模型(P=0.049)。
- 延迟相SPECT/CT影像组学AUC 0.768,显著高于单独CT的0.696(P=0.042)和单独SPECT的0.768(P=0.038)。
临床应用与阅片要点
- 临床模型选用CYFRA21-1构建。
- 延迟相列线图与影像组学模型AUC高于早期相,但无统计学差异(P=0.831、P=0.568)。
局限性
- 这种新方法需要在更大规模的多中心队列中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To establish and validate a technetium 99m sestamibi (99mTc-MIBI) single-photon emission computed tomography/computed tomography (SPECT/CT) nomogram for predicting non-small cell lung cancer (NSCLC). Comparing the diagnostic performance of early and delayed SPECT/CT nomogram, and compare the diagnostic performance of SPECT/CT radiomics models with single SPECT and CT radiomics models.
METHODS: This prospective study included 119 lesions (NSCLC: n = 92, benign pulmonary lesions: n = 27) from 103 patients (mean age: 59.68 ± 8.94 years). Patients underwent dual-phase 99mTc-MIBI SPECT/CT imaging. They were divided into the training (n = 83) and validation (n = 36) cohorts. Logistic regression, support vector machine, random forest, and light-gradient boosting machine were applied to train and determine the optimal machine learning model. Then, combining radiomics score and clinical factors, establish nomograms for diagnosing NSCLC.
RESULT: CYFRA21-1 was selected for constructing the clinical model. In early imaging, the areas under the curve (AUCs) of the clinical model, radiomics model, and nomogram were 0.571, 0.830, and 0.875, respectively. The nomogram performed better than the clinical model and similarly to the radiomics model (P=0.020, P=0.216), and there are no statistically significant differences in the predictive performance between the radiomics model and the clinical model (P=0.103). In delayed imaging, the AUC was 0.643, 0.888, and 0.893, respectively. The predictive performance of the nomogram was superior compared to the clinical model and comparable to the radiomics model (P=0.042, P=0.480), and the radiomics model also demonstrated superior diagnostic performance compared to the clinical model (P=0.049). Compared to early SPECT/CT results, the AUC values of the nomogram and radiomics models in the delayed phase were higher, although no statistical differences were found (P=0.831, P=0.568). In delayed imaging, the AUC of the radiomics models for CT and SPECT was 0.696 and 0.768, respectively, SPECT/CT radiomics exhibited significant differences compared with CT and SPECT alone (P=0.042, P=0.038).
CONCLUSION: Dual-phase 99mTc-MIBI SPECT/CT nomograms and radiomics models can effectively predict NSCLC, providing an economically and non-invasive imaging method for diagnosing NSCLC, moreover, these findings provide a basis for early diagnosis and treatment strategies in NSCLC patients. Delayed-phase SPECT/CT imaging may offer greater practical value than early-phase imaging for diagnosing NSCLC. However, this novel approach necessitates further validation in larger, multi-center cohorts.
CLINICAL RELEVANCE: Radiomics nomogram based on SPECT/CT for discriminating NSCLC from benign lung lesions helps to aid early diagnosis and guide treatment.
KEY POINTS: Nomograms, based on dual-phase SPECT/CT, was constructed to discriminate between non-small cell lung cancer and benign lesions. SPECT/CT radiomics model has better predictive performance than SPECT and CT radiomics model.
引用
- Cheng L, Gao H, Wang Z, et al. Prospective study of dual-phase 99mTc-MIBI SPECT/CT nomogram for differentiating non-small cell lung cancer from benign pulmonary lesions. Eur J Radiol. 2024. PMID: 39163806. doi:10.1016/j.ejrad.2024.111657
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。